4ijf

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 7: Line 7:
==About this Structure==
==About this Structure==
-
[[4ijf]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Ebola_virus_-_mayinga,_zaire,_1976 Ebola virus - mayinga, zaire, 1976]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4IJF OCA].
+
[[4ijf]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Ebozm Ebozm]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4IJF OCA].
==Reference==
==Reference==
<ref group="xtra">PMID:024067086</ref><references group="xtra"/><references/>
<ref group="xtra">PMID:024067086</ref><references group="xtra"/><references/>
-
[[Category: Ebola virus - mayinga, zaire, 1976]]
+
[[Category: Ebozm]]
[[Category: Amarasinghe, G K.]]
[[Category: Amarasinghe, G K.]]
[[Category: Binning, J B.]]
[[Category: Binning, J B.]]

Revision as of 12:28, 11 December 2013

Template:STRUCTURE 4ijf

Contents

Crystal structure of the Zaire ebolavirus VP35 interferon inhibitory domain K222A/R225A/K248A/K251A mutant

Template:ABSTRACT PUBMED 24067086

Function

[VP35_EBOZM] Acsts as a polymerase cofactor in the RNA polymerase transcription and replication complex. Prevents establishment of cellular antiviral state by blocking virus-induced phosphorylation and activation of interferon regulatory factor 3 (IRF3), a transcription factor critical for the induction of interferons alpha and beta. The mechanism by which this blockage occurs remains incompletely defined, a hypothesis suggests that VP35 dsRNA-binding activity prevents activation of IRF3 by sequestering dsRNA. Also inhibits the antiviral effect mediated by the interferon-induced, double-stranded RNA-activated protein kinase EIF2AK2/PKR.[1] [2] [3] [4] [5]

About this Structure

4ijf is a 1 chain structure with sequence from Ebozm. Full crystallographic information is available from OCA.

Reference

  • Binning JM, Wang T, Luthra P, Shabman RS, Borek DM, Liu G, Xu W, Leung DW, Basler CF, Amarasinghe GK. Development of RNA aptamers targeting Ebola virus VP35. Biochemistry. 2013 Sep 26. PMID:24067086 doi:http://dx.doi.org/10.1021/bi400704d
  1. ↑ Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol. 1999 Mar;73(3):2333-42. PMID:9971816
  2. ↑ Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, Garcia-Sastre A, Palese P. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94. PMID:11027311 doi:10.1073/pnas.220398297
  3. ↑ Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, Klenk HD, Palese P, Garcia-Sastre A. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol. 2003 Jul;77(14):7945-56. PMID:12829834
  4. ↑ Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, Kroeker AD, Iversen PL, Bavari S, Muhlberger E. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother. 2006 Mar;50(3):984-93. PMID:16495261 doi:10.1128/AAC.50.3.984-993.2006
  5. ↑ Feng Z, Cerveny M, Yan Z, He B. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol. 2007 Jan;81(1):182-92. Epub 2006 Oct 25. PMID:17065211 doi:JVI.01006-06

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/4ijf"
Personal tools